Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer

Cited by (1,017)

Items 401–500 of 1,017

1. Next Generation Gold Drugs and Probes: Chemistry and Biomedical Applications
   Randall Tyler Mertens, Sailajah Gukathasan, Adedamola S. Arojojoye, Chibuzor Olelewe, Samuel G. Awuah · 2023 · Chemical Reviews
2. Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms
   Huang, Mu-Yang, Jiang, Xiao-Ming, Wang, Bing-Lin, Sun, Yang, Lu, Jin-Jian · 2021 · Pharmacology & Therapeutics
3. Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
   Shixue Chen, Zhibo Zhang, Xuan Zheng, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Yuanyu Qian, Pengfei Cui et al. · 2021 · Frontiers in Oncology
4. Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer
   Giulia Pasello, Alberto Pavan, Ilaria Attili, Alberto Bortolami, Laura Bonanno, Jessica Menis, PierFranco Conte, Valentina Guarneri · 2020 · Cancer Treatment Reviews
5. First-in-Humans Evaluation of a PD-L1–Binding Peptide PET Radiotracer in Non–Small Cell Lung Cancer Patients
   Xin Mei Zhou, Jinquan Jiang, Xue Yang, Teli Liu, Jin Ding, Sridhar Nimmagadda, Martin G. Pomper, Hua Zhu, Jun Zhao, Zhi Yang et al. · 2021 · Journal of Nuclear Medicine
6. New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
   Yang, Haitang, Liang, Shun-Qing, Schmid, Ralph A., Peng, Ren-Wang · 2019 · Frontiers in Oncology
7. Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer
   Mark Kriegsmann, Christian Haag, Cleo‐Aron Weis, Georg Steinbuß, Arne Warth, Christiane Zgorzelski, Thomas Muley, Hauke Winter, Martin Eichhorn, Florian Eichhorn et al. · 2020 · Cancers
8. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
   Patrick M. Forde, Valsamo Anagnostou, Zhuoxin Sun, Suzanne Eleanor Dahlberg, Hedy Lee Kindler, Noushin Niknafs, Thomas Purcell, Rafael Santana-Dávila, Arkadiusz Zbigniew Dudek, Hossein Borghaei et al. · 2021 · Nature Medicine
9. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
   Benjamin Besse, Elvire Pons Tostivint, Keunchil Park, Sylvia Hartl, Patrick M. Forde, Maximilian Johannes Hochmair, Mark Magdi Awad, Michael Thomas, Glenwood D. Goss, Paul Wheatley‐Price et al. · 2024 · Nature Medicine
10. The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy
    Schaer, David A., Geeganage, Sandaruwan, Amaladas, Nelusha, Lu, Zhao Hai, Rasmussen, Erik R., Sonyi, Andreas, Chin, Darin, Capen, Andrew, Li, Yanxia, Meyer, Catalina M. et al. · 2019 · Clinical Cancer Research
11. Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
    Reith Roy Sarkar, Nicholas Joseph Gloude, Deborah E. Schiff, James Don Murphy · 2018 · JNCI Journal of the National Cancer Institute
12. Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
    Navneet Singh, Sarah Temin, Sherman Baker, Elizabeth M. Blanchard, Julie Renee Brahmer, Paul Celano, Narjust Duma, Peter M. Ellis, Ivy Beth Elkins, Rami Y. Haddad et al. · 2022 · Journal of Clinical Oncology
13. Mechanisms of Resistance to Immune Checkpoint Blockade
    David Liu, Russell William Jenkins, Ryan Joseph Sullivan · 2018 · American Journal of Clinical Dermatology
14. The therapeutic implications of immunosuppressive tumor aerobic glycolysis
    Bradley I. Reinfeld, W. Kimryn Rathmell, Tae Kon Kim, Jeffrey C. Rathmell · 2021 · Cellular and Molecular Immunology
15. Current multidisciplinary management of brain metastases
    Michael James Moravan, Peter Edward Fecci, Carey K. Anders, Jeffrey Melson Clarke, April K.S. Salama, Justus D. Adamson, Scott Floyd, Jordan A. Torok, Joseph Kamel Salama, John Howard Sampson et al. · 2020 · Cancer
16. Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
    Sunny Kumar, Mouli Chatterjee, Pratyasha Ghosh, Kirat Kumar Ganguly, Malini Basu, Mrinal K. Ghosh · 2022 · Genes & Diseases
17. Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors
    Paul W. Sperduto, Brian S. De, Jing Li, David James Carpenter, John P. Kirkpatrick, Michael Milligan, Helen Alice Shih, Tuğçe Kütük, Rupesh R Kotecha, Hajime Higaki et al. · 2022 · International Journal of Radiation Oncology*Biology*Physics
18. Current status of immune checkpoint inhibition in early-stage NSCLC
    Johan Vansteenkiste, Els Wauters, Bart J.T. Reymen, Christoph Jakob Ackermann, Solange Peters, Dirk De Ruysscher · 2019 · Annals of Oncology
19. Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer
    Kathryn Cecilia Arbour, Hira A. Rizvi, Andrew J. Plodkowski, Matthew David Hellmann, Andrea Knežević, Glenn Heller, Helena Alexandra Yu, Marc Ladanyi, Mark G. Kris, Maria E. Arcila et al. · 2021 · Clinical Cancer Research
20. Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy
    Hellmann, Matthew D., Jänne, Pasi A., Opyrchal, Mateusz, Hafez, Navid, Raez, Luis E., Gabrilovich, Dmitry I., Wang, Fang, Trepel, Jane B., Lee, Min-Jung, Yuno, Akira et al. · 2021 · Clinical Cancer Research
21. Increasing cure rates of solid tumors by immune checkpoint inhibitors
    Weijie Ma, Ruobing Xue, Zheng Gang Zhu, Hizra Farrukh, Wenru Song, Tianhong Li, Lei Zheng, Chong-xian Pan · 2023 · Experimental Hematology and Oncology
22. Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance
    Hannah Noelle Bell, Weiping Zou · 2024 · Annual Review of Immunology
23. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non–Small Cell Lung Cancer: A Nonrandomized Controlled Trial
    Jabbour, Salma K., Berman, Abigail T., Decker, Roy H., Lin, Yong, Feigenberg, Steven J., Gettinger, Scott N., Aggarwal, Charu, Langer, Corey J., Simone, Charles B., Bradley, Jeffrey D. et al. · 2020 · JAMA Oncology
24. Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Lorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, Nadia Barraco, Marco Bono, Lidia Rita Corsini, Antonio Galvano, Valerio Gristina, Angela Listì, Salvatore Vieni et al. · 2019 · Advances in Therapy
25. Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non–Small Cell Lung Cancer
    Youngtae Jeong, Jessica A. Hellyer, Henning Stehr, Ngoc T. Hoang, Xiaomin Niu, Millie Snigdha Das, Sukhmani Kaur Padda, Kavitha J. Ramchandran, Joel W. Neal, Heather A. Wakelee et al. · 2019 · Clinical Cancer Research
26. Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
    Matthew David Hellmann, Barzin Y. Nabet, Hira A. Rizvi, Aadel A. Chaudhuri, Daniel K. Wells, Mark P. Dunphy, Jacob J. Chabon, Chih Long Liu, Angela Bik‐Yu Hui, Kathryn Cecilia Arbour et al. · 2020 · Clinical Cancer Research
27. The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma
    Shaodong Hong, Dongbing Liu, Shuzhen Luo, Wenfeng Fang, Jianhua Zhan, Sha Fu, Yaxiong Zhang, Xuan Wu, Huaqiang Zhou, Xi Chen et al. · 2019 · Nature Communications
28. Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis
    Matteo Giaj Levra, François-Emery Cotté, R. Corre, Christophe Yannick Calvet, Anne-Françoise Gaudin, John R. Penrod, V. Grumberg, Baptiste Jouaneton, Ronan Jolivel, Jean‐Baptiste Assié et al. · 2019 · Lung Cancer
29. Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy
    Yuan Cheng, Tao Zhang, Qing Xu · 2021 · MedComm
30. Immunosurveillance in clinical cancer management
    Guido Kroemer, Timothy An-thy Chan, Alexander M.M. Eggermont, Lorenzo Galluzzi · 2023 · CA A Cancer Journal for Clinicians
31. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors
    Nassar, Amin H., Adib, Elio, Abou Alaiwi, Sarah, El Zarif, Talal, Groha, Stefan, Akl, Elie W., Nuzzo, Pier Vitale, Mouhieddine, Tarek H., Perea-Chamblee, Tomin, Taraszka, Kodi et al. · 2022 · Cancer Cell
32. Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy
    Daniel R. Principe, Matthew Narbutis, Sandeep Kumar, Alex J. Park, Navin Viswakarma, Matthew J. Dorman, Suneel Deepak Kamath, Paul J. Grippo, Melissa L. Fishel, Rosa F. Hwang et al. · 2020 · Cancer Research
33. The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials
    Antonio Galvano, Valerio Gristina, Umberto Malapelle, Pasquale Pisapia, Francesco Pepe, Nadia Barraco, Marta Castiglia, Alessandro Perez, Christian Diego Rolfo, Giancarlo Troncone et al. · 2021 · ESMO Open
34. Role of NRF2 in Lung Cancer
    Miriam Sánchez-Ortega, Ana Clara Carrera, António Garrido · 2021 · Cells
35. Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer
    Veronica Ghini, Letizia Laera, Beatrice Fantechi, Francesca Del Monte, Matteo Benelli, Amelia McCartney, Leonardo Tenori, Claudio Luchinat, Daniele Pozzessere · 2020 · Cancers
36. The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment
    Jia‐Wei Lv, Wei Yuan, Jianhua Yin, Yu‐Pei Chen, Guan‐Qun Zhou, Wei Chen, Xiaoyu Liang, Yuan Zhang, Cuijuan Zhang, Shiwei He et al. · 2023 · Nature Medicine
37. Adenosquamous carcinoma of the lung
    Chenghui Li, Hongyang Lu · 2018 · OncoTargets and Therapy
38. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors
    Fumihiro Shoji, Hiroaki Takeoka, Yuka Kozuma, Gouji Toyokawa, Koji Yamazaki, Masao Ichiki, Sadanori Takeo · 2019 · Lung Cancer
39. A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed
    Shuncong Wang, Yewei Liu, Yuanbo Feng, Jian Zhang, Johannes V. Swinnen, Yue Li, Yicheng Ni · 2019 · Cancers
40. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials
    Fang Yang, Svetomir N. Markovic, Julian R. Molina, Thorvardur Ragnar Halfdanarson, Lance C. Pagliaro, Ashish Vittalrao Chintakuntlawar, Rutian Li, Jia Wei, Lifeng Wang, Baorui Liu et al. · 2020 · JAMA Network Open
41. Pharmacologic management of cognitive impairment induced by cancer therapy
    Philipp Karschnia, Michael W. Parsons, Jörg Dietrich · 2019 · The Lancet Oncology
42. The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis
    Rupesh R Kotecha, Joseph M. Kim, Jacob A. Miller, Aditya Juloori, Samuel T. Chao, Erin Sennett Murphy, David M. Peereboom, Alireza Mohammad Mohammadi, Gene H. Barnett, Michael A. Vogelbaum et al. · 2019 · Neuro-Oncology
43. Immune checkpoint inhibitors win the 2018 Nobel Prize
    Pei‐Wei Huang, John Wen‐Cheng Chang · 2019 · Biomedical Journal
44. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
    Neil J. Shah, Ghassan Al‐Shbool, Matthew J. Blackburn, Michael Roderick Cook, Anas Belouali, Stephen V. Liu, Subha Madhavan, Aiwu Ruth He, Michael B. Atkins, Geoffrey Thomas Gibney et al. · 2019 · Journal for ImmunoTherapy of Cancer
45. SMARCA4: Current status and future perspectives in non-small-cell lung cancer
    Yumeng Tian, Lu Xu, Xin Li, Heming Li, Mingfang Zhao · 2022 · Cancer Letters
46. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
    Tatsuya Nagano, Motoko Yoshikawa TACHIHARA, Yoshihiro Nishimura · 2018 · Current Cancer Drug Targets
47. PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell–inflamed phenotype
    James K. Godfrey, Sravya Tumuluru, Riyue Bao, Michael J. Leukam, Girish Venkataraman, John Phillip, Carrie A. Fitzpatrick, James McElherne, Brendan W. MacNabb, Robert J. Orlowski et al. · 2019 · Blood
48. Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
    Michael David Offin, Robin Guo, Stephanie L. Wu, Joshua K. Sabari, Josiah D. Land, Ai Ni, Joseph Montecalvo, Darragh F. Halpenny, Larry W. Buie, Terry Pak et al. · 2019 · JCO Precision Oncology
49. Emerging therapies in advanced hepatocellular carcinoma
    Sowmini Medavaram, Yue Zhang · 2018 · Experimental Hematology and Oncology
50. Targeting phosphatidylserine for Cancer therapy: prospects and challenges
    Wenguang Chang, Hongge Fa, Dandan Xiao, Jianxun Wang · 2020 · Theranostics
51. Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade
    Lander, Varintra E., Belle, Jad I., Kingston, Natalie L., Herndon, John M., Hogg, Graham D., Liu, Xiuting, Kang, Liang-I, Knolhoff, Brett L., Bogner, Savannah J., Baer, John M. et al. · 2022 · Cancer Discovery
52. Immune Checkpoint Inhibitors in Real‐World Treatment of Older Adults with Non–Small Cell Lung Cancer
    Eugene Muchnik, Kah Poh Loh, Myla S. Strawderman, Allison M. Magnuson, Supriya Gupta Mohile, Vered Estrah, Ronald John Maggiore · 2019 · Journal of the American Geriatrics Society
53. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50%
    Justin F. Gainor, Hira A. Rizvi, E. Jimenez Aguilar, Ferdinandos Skoulidis, Beow Yong Yeap, Jarushka Naidoo, S. Khosrowjerdi, Meghan J. Mooradian, Caitlin M. Lydon, Peter Bela Illei et al. · 2020 · Annals of Oncology
54. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma
    Jeffrey C. Thompson, Christiana W. Davis, Charuhas G. Deshpande, Wei‐Ting Hwang, Seth Jeffries, Alexander Chan Chi Huang, Tara C. Mitchell, Corey Jay Langer, Steven Μ. Albelda · 2020 · Journal for ImmunoTherapy of Cancer
55. Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management
    Qin Zhang, Liansha Tang, Yuwen Zhou, Wenbo He, Weimin Li · 2021 · Frontiers in Immunology
56. Immune checkpoint Inhibitor–Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis
    Dorte Lisbet Nielsen, Carsten Bogh Juhl, Inna Markovna Chen, Lauge Kellermann, Ole Haagen Nielsen · 2022 · Cancer Treatment Reviews
57. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients
    Luca Cantini, Federica Pecci, Daan P. Hurkmans, Robert A. Belderbos, Andrea Lanese, Cecilia Copparoni, Sophie Aerts, Robin Cornelissen, Daphne W. Dumoulin, Ilaria Fiordoliva et al. · 2020 · European Journal of Cancer
58. Combinatorial therapy in tumor microenvironment: Where do we stand?
    Smita Kumari, Dia Advani, Sudhanshu Sharma, Rashmi K. Ambasta, Pravir Kumar · 2021 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
59. Worldwide research trends on tumor burden and immunotherapy: a bibliometric analysis
    Lei Zhang, Han Zheng, Shitao Jiang, Yao-Ge Liu, Ting Zhang, Junwei Zhang, Xin Lü, Haitao Zhao, Xinting Sang, Yiyao Xu · 2024 · International Journal of Surgery
60. A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study
    Han Si, Michael A. Kuziora, Katie Quinn, Elena Helman, Jiabu Ye, Feng Liu, Urban J. Scheuring, Solange Peters, Naiyer A. Rizvi, Philip Z. Brohawn et al. · 2020 · Clinical Cancer Research
61. Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC
    Yasuto Yoneshima, Satoshi Morita, Masahiko Ando, Atsushi Nakamura, Shunichiro Iwasawa, Hiroshige Yoshioka, Yasuhiro Gotô, Masafumi Takeshita, Toshiyuki Harada, Katsuya Hirano et al. · 2021 · Journal of Thoracic Oncology
62. The complementarity of DDR, nucleic acids and anti-tumour immunity
    Anand V. R. Kornepati, Cody M. Rogers, Patrick Sung, Tyler Jay Curiel · 2023 · Nature
63. Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
    Elizabeth Stephanie Ahern, Mark John Smyth, William C. Dougall, Michele W.L. Teng · 2018 · Nature Reviews Clinical Oncology
64. Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights
    Catherine Belle Meador, Aaron N. Hata · 2020 · Pharmacology & Therapeutics
65. Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial
    Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze, Ana Baramidze, Davit Giorgadze, Konstantin Penkov, Константин Константинович Лактионов, Gia Nemsadze, Marina Nechaeva, Irina Rozhkova et al. · 2023 · Journal of Thoracic Oncology
66. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer
    Marcelo Vailati Negrao, Vincent K. L. Lam, Alexandre Reuben, Maria Laura Rubin, L.L. Landry, Emily B. Roarty, Waree Rinsurongkawong, Jeff Lewis, Jack A. Roth, Stephen G. Swisher et al. · 2019 · Journal of Thoracic Oncology
67. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non–Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors
    Jun Fukihara, Koji Sakamoto, Junji Koyama, Takayasu Ito, Shingo Iwano, Masahiro Morise, Masahiro Ogawa, Yasuhiro Kondoh, Tomoki Kimura, Naozumi Hashimoto et al. · 2019 · Clinical Lung Cancer
68. Clinical Insights Into Novel Immune Checkpoint Inhibitors
    Jii Bum Lee, Sang‐Jun Ha, Hye Ryun Kim · 2021 · Frontiers in Pharmacology
69. Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
    Katrin Pansy, Barbara Uhl, Jelena Krstić, Marta Szmyra, Karoline Fechter, Ana Santiso, Lea Thüminger, Hildegard Greinix, Julia Kargl, Katharina Theresa Prochazka et al. · 2021 · International Journal of Molecular Sciences
70. Tumor metastasis: Mechanistic insights and therapeutic interventions
    Mengmeng Liu, Jing Yang, Bu-Shu Xu, Xing Zhang · 2021 · MedComm
71. PD-L1 testing by immunohistochemistry in immuno-oncology
    Semir Vranić, Zoran Gatalica · 2022 · Biomolecules and Biomedicine
72. Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature
    Jan Norum, Carsten Nieder · 2018 · ESMO Open
73. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition
    Aida Karachi, Changlin Yang, Farhad Dastmalchi, Elias Joseph Sayour, Jianping Huang, Hassan Azari, Yu Long, Catherine Flores, Duane A. Mitchell, Maryam Rahman · 2019 · Neuro-Oncology
74. Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set
    Sandra D. Griffith, Rebecca Anne Miksad, Geoff Calkins, Paul You, Nicole G. Lipitz, Ariel Bulua Bourla, Erin Williams, Daniel J. George, Deborah Schrag, Sean Khozin et al. · 2019 · JCO Clinical Cancer Informatics
75. The current treatment landscape in the UK for stage III NSCLC
    on behalf of AstraZeneca UK Limited, Matthew Evison · 2020 · British Journal of Cancer
76. Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
    Antonino Grassadonia, Isabella Sperduti, Patrizia Vici, Laura Iezzi, Davide Brocco, Teresa Gamucci, Laura Pizzuti, Marcello Maugeri‐Saccà, Paolo Marchetti, Gaetana Cognetti et al. · 2018 · Journal of Clinical Medicine
77. Comparing the effects of different cell death programs in tumor progression and immunotherapy
    Michelle Nicole Messmer, Annelise G. Snyder, Andrew Oberst · 2018 · Cell Death and Differentiation
78. Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
    Jacques L. Cadranel, Anthony Canellas, Lise Matton, Marie Darrason, A. Parrot, Jean‐Marc Naccache, A. Lavolé, Anne-Marie Ruppert, Vincent Fallet · 2019 · European Respiratory Review
79. Directing Traffic: How to Effectively Drive T Cells into Tumors
    Annabelle J. Anandappa, Catherine J. Wu, Patrick Alexander Ott · 2020 · Cancer Discovery
80. Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis
    Alessandro Rizzo, Antonio Cusmai, Francesco Giovannelli, Silvana Acquafredda, Lucia Rinaldi, Andrea Misino, Elisabetta Sara Montagna, Valentina Ungaro, Mariagrazia Lorusso, Gennaro Palmiotti · 2022 · Cancers
81. Effect of corticosteroids on the outcome of patients with advanced non–small cell lung cancer treated with immune-checkpoint inhibitors
    Marcus Skribek, Konstantinos Rounis, Soren Afshar, Oscar Grundberg, Signe Friesland, Georgios Tsakonas, Simon Ekman, Luigi De Petris · 2021 · European Journal of Cancer
82. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
    Quincy Siu-Chung Chu, Federica Perrone, Laurent Greillier, Wei Tu, Maria Carmela Piccirillo, Federica Grosso, Giuseppe Lo Russo, Marie Florescu, Manlio Mencoboni, Alessandro Morabito et al. · 2023 · The Lancet
83. Drug Discovery for Kinetoplastid Diseases: Future Directions
    Srinivasa P. S. Rao, Michael Peter Barrett, Glenn Dranoff, Christopher J. Faraday, Claudio R. Gimpelewicz, Asrat Hailu, Catherine L. Jones, John M. Kelly, Janis K. Lazdins-Helds, Pascal Mäser et al. · 2018 · ACS Infectious Diseases
84. How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer
    Solange Peters, Martin Reck, Egbert Frederik Smit, Tony S.K. Mok, Matthew David Hellmann · 2019 · Annals of Oncology
85. Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer
    Li Zhou, Qiuli Xu, Litang Huang, Jiajia Jin, Xueying Zuo, Qun Zhang, Liang Ye, Suhua Zhu, Ping Zhan, Jianan Ren et al. · 2020 · Cancer Letters
86. Cancer cell-intrinsic mechanisms driving acquired immune tolerance
    Ehsan Ghorani, Charles Swanton, Sergio A. Quezada · 2023 · Immunity
87. Prognostic Impact of Tumor-Infiltrating Lymphocytes and Neutrophils on Survival of Patients with Upfront Resection of Pancreatic Cancer
    Rainer Christoph Miksch, Markus Bo Schoenberg, Maximilian Weniger, Florian Bösch, Steffen Ormanns, Barbara Mayer, Jens Werner, Alexandr V. Bazhin, Jan Goesta D’Haese · 2019 · Cancers
88. Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer
    Robert Pirker · 2019 · Current Opinion in Oncology
89. Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
    Paola Ciciola, Priscilla Cascetta, Cataldo Bianco, Luigi Formisano, Roberto Bianco · 2020 · Journal of Clinical Medicine
90. Adjuvant and Neoadjuvant Immunotherapy in Non–small Cell Lung Cancer
    Stephen Broderick · 2020 · Thoracic surgery clinics/Thorac. surg. clin.
91. Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
    Sandra M. Herrmann, Mark Anthony Perazella · 2020 · Kidney International Reports
92. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy
    Jeffrey C. Thompson, Erica L. Carpenter, Benjamin A. Silva, J Rosenstein, Austin L. Chien, Katie Quinn, Carin R. Espenschied, Allysia J. Mak, Lesli Ann Kiedrowski, Martina I. Lefterova et al. · 2021 · JCO Precision Oncology
93. Aptamer-Based Logic Computing Reaction on Living Cells to Enable Non-Antibody Immune Checkpoint Blockade Therapy
    Yu Pu Yang, Jun Xu, Yang Sun, Liuting Mo, Bo Liu, Xiaoshu Pan, Zhuang Liu, Weihong Tan · 2021 · Journal of the American Chemical Society
94. Small cell lung cancer: Novel treatments beyond immunotherapy
    Job-Joris Meijer, Alessandro Leonetti, Giulia Airò, Marcello Tiseo, Christian Diego Rolfo, Elisa Giovannetti, Mahrou Vahabi · 2022 · Seminars in Cancer Biology
95. Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
    Tang, Kwan Ho, Li, Shuai, Khodadadi-Jamayran, Alireza, Jen, Jayu, Han, Han, Guidry, Kayla, Chen, Ting, Hao, Yuan, Fedele, Carmine, Zebala, John A. et al. · 2022 · Cancer Discovery
96. Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis
    Jong Yeob Kim, Keum Hwa Lee, Jeonghyun Kang, Édith Borcoman, Esma Saâda-Bouzid, Andreas Kronbichler, Sung Hwi Hong, Leandro F. M. Rezende, Shuji Ogino, NaNa Keum et al. · 2019 · Cancers
97. Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
    Ami N. Shah, Lisa Flaum, Irene Helenowski, Cesar Augusto Santa-Maria, Sarika Jain, ALFRED W. RADEMAKER, Valerie M. Nelson, Dean Tsarwhas, Massimo Cristofanilli, William John Gradishar · 2020 · Journal for ImmunoTherapy of Cancer
98. STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
    Alessandro Di Federico, Andrea De Giglio, Claudia Parisi, Francesco Gelsomino · 2021 · European Journal of Cancer
99. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
    Stanley I. Gutiontov, William Tyler Turchan, Liam Flinn Spurr, Sherin Juliet Rouhani, Carolina Soto Chervin, George Steinhardt, Angela M. Lager, Pankhuri Wanjari, Renuka Malik, Philip P. Connell et al. · 2021 · Scientific Reports
100. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials
     Borghaei, Hossein, Langer, Corey J., Paz‐Ares, Luis, Rodríguez‐Abreu, Delvys, Halmos, Balazs, Garassino, Marina C., Houghton, Baerin, Kurata, Takayasu, Cheng, Ying, Lin, Jianxin et al. · 2020 · Cancer